Connect with us

Wellness

Single blood test predicts 30-year cardiovascular disease risks for women

Published

on

New research has found that measuring two types of fat in the bloodstream along with C-reactive protein (CRP), a marker of inflammation, can predict a woman’s risk for cardiovascular disease decades later.

For the study, investigators collected blood samples and medical information from 27,939 health care providers living in the United States who participated in the Women’s Health Study.

Women, who started the study between 1992 to 1995 at an average age of 55, were followed for 30 years.

During this period, 3,662 study participants experienced a heart attack, stroke, surgery to restore circulation, or a cardiovascular-related death. Researchers assessed how high-sensitivity CRP, along with low-density lipoprotein (LDL) cholesterol and lipoprotein(a), or Lp(a), a lipid partly made of LDL, singularly and collectively predicted these events.

Participants were grouped into five categories — ranging from those with the highest to lowest levels — to measure each of the three markers. Researchers found that women with the highest levels of LDL cholesterol had a 36 per cent increased associated risk for heart disease compared to those with the lowest levels.

Those with the highest levels of Lp(a) had a 33 per cent increased associated risk, and those with the highest levels of CRP had a 70 per cent increased associated risk.

When all three measures — LDL cholesterol, Lp(a), and CRP — were assessed together, participants with the highest levels had more than a 1.5-times increased associated risk for stroke and more than a three-times increased associated risk for coronary heart disease compared to women with the lowest levels.

The researchers note that while only women were assessed in this study, they would expect to find similar results in men.

“We can’t treat what we don’t measure, and we hope these findings move the field closer to identifying even earlier ways to detect and prevent heart disease,” said Paul M. Ridker, M.D., M.P.H., a study author and the director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston.

“In recent years, we’ve learned more about how increased levels of inflammation can interact with lipids to compound cardiovascular disease risks,” added Ahmed A.K. Hasan, M.D., Ph.D., a medical officer and program director at NIH’s National Heart, Lung, and Blood Institute (NHLBI).

“This helps explain why lower levels are often better.”

Immune cells, which help the body repair itself from wounds or infection, can also sense the accumulation of extra cholesterol in cells or become activated in response to the build-up of plaque and send out inflammatory signals.

This creates a hyperinflammatory environment where plaque can form, become larger, or even rupture — and cause cardiovascular events.

To support optimal cardiovascular health, the researchers emphasize primary prevention. This includes getting regular physical activity, eating a heart-healthful diet, managing stress, and avoiding tobacco or quitting smoking.

Other measures for people with increased risks may include using medication to lower cholesterol and/or reduce inflammation. Researchers have also found that steps people take earlier in life to support their heart and vascular health can add up over time and correlate with better health outcomes years and even decades later.

LDL cholesterol, which is routinely measured by healthcare providers, can be treated with widely available therapies, such as statins. However, standard Lp(a) and CRP screening recommendations can vary.

Some countries recommend screening for Lp(a) since elevated levels are often due to inherited risks. In areas without universal Lp(a) screenings, like the U.S., physicians can order tests for people with heart disease or who have a family history of it.

Some therapies are available for those with elevated levels and researchers are testing new approaches to personalise and improve treatment options.

Testing for CRP also varies. Screening often depends on a person’s underlying risks or is up to the discretion of the provider.

Colchicine, an anti-inflammatory therapy previously used for gout, was approved by the Food and Drug Administration in 2023 to offset risks for cardiovascular disease among people with atherosclerosis. Additional anti-inflammatory therapies and approaches are being studied.

The findings were presented at the European Society of Cardiology Congress 2024 and published in the New England Journal of Medicine.

News

Just 30 mins of light activity can boost energy and mood, study finds

Published

on

Swapping just 30 minutes of sitting for light activity, such as walking or housework, can improve mood and energy the following day, new research suggests.

A study involving more than 350 young adults found that on days when participants spent less time sitting and more time doing light activity, they felt happier and more energised the next day.

Researchers said light activity had the strongest link to improved next-day mood, while time spent sitting or lying awake was associated with poorer mood the following day.

The study, led by the University of Texas at Arlington and Monash University in Australia, tracked participants’ 24-hour movement patterns using wearable monitors.

“This study indicated that light activity — where you don’t have to go to the gym or do intense exercise — can lead to better feelings the next day when it replaces sedentary behaviour,” said Dr Yue Liao, kinesiology professor at UT Arlington.

“One doesn’t have to think, ‘I have to run,’ or ‘I have to do these big things.’ Just sitting less and moving more can have an immediate impact on your mood the next day.”

The findings are particularly relevant as 38 per cent of US adults spend nine or more hours sitting each day, according to a 2024 study by smart seating company Kalogon.

Researchers analysed daily activity across sleep, exercise, sedentary time and light movement. Moderate to vigorous activity, such as running or gym workouts, offered smaller mood benefits, while sleep duration showed no clear effect on next-day mood among participants.

“We looked at the 24-hour movement behaviour — sleep, exercise, sedentary time and light activity,” said Dr Liao.

“The 24-hour part is important because we’re not simply saying, ‘Do more of this.’ All these activities add up to 24 hours. From that perspective, when someone replaces sitting time with light activity, it predicts a better mood the next day. That’s the key point.”

The improvements were based on individual changes rather than comparisons between participants.

“Based on previous research, we assumed exercise would be the main factor, but our analysis mostly highlighted light activity,” Dr Liao said.

“You don’t have to work up a sweat to get benefits. Just moving a little more than your usual helps.”

The study suggests that small, everyday adjustments — such as standing up more often or walking briefly — can make a noticeable difference to wellbeing, the researchers concluded.

Continue Reading

News

Night-time light exposure may increase stroke and heart attack risk

Published

on

Bright light at night raises the risk of heart attack by 47 per cent and heart failure by 56 per cent, according to research involving nearly 89,000 people.

Being exposed to bright light at night could significantly increase the chances of developing serious heart problems, including heart attacks, strokes and heart failure.

The largest study of its kind tracked over 13 million hours of light exposure using wrist-worn sensors and followed participants for up to 9.5 years.

Those exposed to the brightest light at night were 56 per cent more likely to develop heart failure and 47 per cent more likely to suffer a heart attack. These risks remained high even after accounting for factors such as exercise, diet, sleep habits and genetics.

Researchers from Flinders University’s FHMRI Sleep Health analysed data from almost 89,000 people in the UK to investigate how personal light exposure affects heart health.

Dr Daniel Windred, lead author and research associate at Flinders University’s FHMRI Sleep Health, said the study highlights a risk factor many people overlook — one that is simple to address.

“This is the first large-scale study to show that simply being exposed to light at night is a strong and independent risk factor for heart disease,” said Dr Windred.

“Disrupting your body’s internal circadian clock by repeatedly exposing yourself to bright light at night, when it would typically be dark otherwise, will put you at a higher risk of developing dangerous heart issues.

“Thankfully, we do have some control over our exposure to light at night.

“By using blackout curtains, dimming lights, and avoiding screens before bed, we can help to reduce the health risks associated with light at night.”

The study also found that women and younger people were especially vulnerable to the effects of light exposure at night.

“Women may be more sensitive to the effects of light disrupting their body clock, which supports earlier research findings,” said senior co-author Professor Sean Cain.

“In fact, women exposed to high levels of night light had similar heart failure risks to men, which is unusual because women typically have some natural protection against heart disease.”

Everyday behaviours may also pose risks, added senior co-author Associate Professor Andrew Phillips.

“Everyday habits, like scrolling on your phone in bed or falling asleep with the TV on or bedroom lights on, can expose you to potentially harmful levels of light,” said Associate Professor Phillips from FHMRI Sleep Health.

“We’re not talking about extreme cases — even low levels of indoor light can interfere with your body’s natural rhythm.”

Unlike previous studies that relied on satellite images or surveys of outdoor light at night, this research used real-time data from wearable devices, providing a clearer picture of how indoor light environments affect health.

The circadian clock — the body’s internal timing system — regulates sleep-wake cycles and other biological processes over about 24 hours.

With heart disease still the leading cause of death worldwide, the researchers say it is time to treat light at night as a health risk, alongside poor diet, lack of exercise and smoking.

The team is calling for more research into lighting guidelines for homes, hospitals and cities to help reduce night-time light exposure.

“We need to take our body clocks seriously,” said Professor Cain.

“Protecting our natural sleep rhythms could be a powerful way to fight heart disease.”

Continue Reading

News

Weight loss drug reduces heart attack and stroke risk regardless of weight loss

Published

on

Semaglutide reduces the risk of heart attack and stroke by 20 per cent, regardless of weight lost, according to the largest study of 17,604 patients.

The drug, the main ingredient in Wegovy, reduced the risk of major adverse cardiac events — including deaths from heart disease, heart attacks or strokes — by 20 per cent, regardless of the weight patients lost.

The findings suggest the drug may have wider benefits beyond weight loss and should not be restricted only to those with the highest body mass index (BMI).

The study, led by researchers at University College London, examined data from 17,604 adults aged 45 and over who were overweight or obese across 41 countries. Half received weekly injections of semaglutide, while the other half were given a placebo.

Previous analysis had already shown semaglutide’s 20 per cent reduction in cardiac events; this follow-up analysis confirmed the benefit remained even when weight loss was minimal.

Even participants who were only mildly overweight — with a BMI of 27, roughly the UK average — saw similar benefits to those with the highest BMI scores.

The benefits were also largely independent of how much weight people lost in the first four months of treatment.

However, a reduction in waist circumference — a measure of abdominal fat — explained about one-third of the observed cardiovascular benefits.

Professor John Deanfield, from UCL’s Institute of Cardiovascular Science, said: “Abdominal fat is more dangerous for our cardiovascular health than overall weight and therefore it is not surprising to see a link between reduction in waist size and cardiovascular benefit.

“However, this still leaves two-thirds of the heart benefits of semaglutide unexplained. These findings reframe what we think this medication is doing.

“It is labelled as a weight-loss jab but its benefits for the heart are not directly related to the amount of weight lost – in fact, it is a drug that directly affects heart disease and other diseases of ageing.”

He added: “This work has implications for how semaglutide is used in clinical practice.

“You don’t have to lose a lot of weight and you don’t need a high BMI to gain cardiovascular benefit. If your aim is to reduce cardiovascular disease, restricting its use to a limited time only and for those with the highest BMIs doesn’t make sense.

“At the same time, the benefits need to be weighed against potential side-effects. Investigations of side-effects become especially important given the broad range of people this medicine and others like it could help.”

The Select trial findings indicate that semaglutide’s cardiovascular effects are likely driven by multiple mechanisms rather than weight loss alone.

While shrinking waistlines contributed to the outcome, most of the heart benefit appears to stem from other biological effects that directly influence cardiovascular pathways.

Continue Reading

Trending

Agetech World